Amy B. Middleman, MD, MSEd, MPH, an
Infectious Diseases in Children Editorial Board member, and colleagues evaluated 420 adolescents aged 16 to 19 years who received a recombinant
hepatitis B virus (HBV)
vaccine
three-dose series to determine protective titers of antibody to
hepatitis B surface antigen (HBsAg) before and after a challenge dose of
the vaccine. Participants were divided in to two groups, those who had
the series initiation within 7 days of birth (group 1) or at 4 weeks or
more following birth (group 2).